The Nicotine Pouch Explosion: Why 2025 Was the Year Oral Nicotine Went Mainstream

In 2019, Zyn nicotine pouches were a curiosity—a small brand in a small category, known mainly to Swedish expatriates and nicotine enthusiasts. By 2025, Zyn had become a cultural phenomenon. TikTok was flooded with 'Zynfluencers'—young men, predominantly, posting videos with the distinctive round can visible in their upper lip. The brand had become a verb ('I'm Zynning through this meeting') and a lifestyle signifier (the can, displayed on a desk, signaling a certain kind of productivity-obsessed, conspicuously unbothered masculinity). Sales had grown by triple-digit percentages annually for five consecutive years. Philip Morris International, which acquired Zyn's manufacturer Swedish Match in 2022, was reporting that the brand alone was generating billions in revenue and accelerating the company's 'smoke-free' transition. The nicotine pouch, a product that barely existed outside Scandinavia a decade earlier, had gone mainstream. The speed and scale of the transformation demand explanation—and raise urgent questions about what the mainstreaming of oral nicotine means for public health.

The drivers of the nicotine pouch explosion are multiple and mutually reinforcing. The product itself has inherent advantages: discretion (no smoke, no vapor, no smell, no spitting), simplicity (open can, place pouch, discard), and a pharmacokinetic profile that falls between the rapid hit of vaping and the slow onset of NRT—satisfying without being as compulsively redosable as a cigarette. The cultural moment was right: the destigmatization of nicotine (driven by vaping's normalization), the optimization culture (nicotine as nootropic, not addiction), and the post-COVID shift toward products that can be used anywhere (pouches on planes, in offices, during meetings). And the industry's marketing was sophisticated: Zyn's advertising avoided the youth-targeted aesthetics that got JUUL in trouble, instead positioning the product as a clean, modern, adult nicotine solution—' nicotine, reimagined.' The combination of product, culture, and marketing created a category that grew faster than any nicotine product since the cigarette itself.

The demographics of the pouch explosion tell a complex story that challenges simple narratives about nicotine product adoption. Unlike vaping, which attracted large numbers of never-smokers (particularly youth), pouch adoption has been concentrated among existing nicotine users—primarily former smokers and vapers, but also dual-users looking for a product that can be used in smoke-free and vape-free environments. The never-smoker initiation rate for pouches is lower than for vaping but not zero, and it's increasing—particularly among young adult males who encounter pouches through social media and peer networks rather than through a smoking-to-pouch transition pathway. The demographic profile is notably gendered: pouch use skews heavily male (roughly 70–80% in most surveys), in contrast to vaping, which achieved greater gender balance. The reasons for this gender skew are not fully understood but likely involve the product's association with male-coded qualities (discretion, control, productivity) and its marketing through male-dominated social media channels.

The public health implications of the pouch explosion are genuinely uncertain and polarized along predictable lines. Harm-reduction advocates see pouches as the most promising development in nicotine since vaping—a product that's almost certainly lower-risk than both smoking and vaping (no combustion, no inhalation, no tobacco-specific nitrosamines at significant levels), that's attracting existing nicotine users rather than never-users, and that could accelerate the decline of both smoking and vaping by providing a satisfying, discreet alternative. Precautionary advocates see pouches as the next wave of the nicotine epidemic—a product that's normalizing nicotine use among demographics that had moved away from it, that's being marketed with the same sophisticated techniques that made vaping a youth crisis, and whose long-term health effects are unknown. Both interpretations find support in the available data. The evidence that would resolve the dispute—longitudinal studies tracking pouch users' health outcomes and smoking trajectories over decades—doesn't exist yet.

The regulatory response to the pouch explosion has been characteristically fragmented and delayed. In the United States, the FDA has authorized several pouch products through the PMTA pathway, implicitly accepting that they're 'appropriate for the protection of public health' while not endorsing them as safe. In the EU, the regulatory status of pouches varies by member state—legal and largely unregulated in some, restricted or prohibited in others—creating the same regulatory patchwork that characterized early vaping regulation. In LMICs, pouches are entering markets with essentially no regulatory framework, raising concerns about youth marketing and product safety in the absence of oversight. The WHO's May 2026 warning about pouch marketing to youth signals that the international public health community is beginning to engage with the category, but the engagement is reactive—the products are already on the market, the consumers are already using them, and the regulatory framework is being built around an existing reality rather than anticipating an emerging one.

The pouch explosion's most significant long-term impact may be on the trajectory of the cigarette market. If pouches continue to attract smokers and vapers—and if the regulatory environment allows them to compete on price and accessibility with combustible products—they could accelerate smoking's decline in ways that vaping, constrained by flavor bans, device complexity, and social stigma, has not fully achieved. The 'Zyn effect'—the observation that cigarette sales decline faster in markets with high pouch adoption—is not yet established with rigorous evidence, but the Swedish experience with snus provides a compelling historical precedent: when oral nicotine products are widely available, affordable, and socially acceptable, smokers switch. The pouch's key advantage over vaping in this respect is its simplicity: there's no device to learn, no battery to charge, no coil to replace. The barrier to switching from cigarettes to pouches is lower than the barrier to switching to vaping—and lower barriers mean more switches.

The nicotine pouch explosion is not a passing fad. It's a structural shift in how nicotine is consumed, driven by the same forces that drove the shift from smoking to vaping—product innovation, cultural change, and consumer demand for nicotine without combustion. Whether the shift is a public health triumph or a public health threat will be determined by regulation: by whether pouches are allowed to compete on price with cigarettes, by whether youth marketing is effectively restricted, by whether honest risk communication enables informed consumer choice, and by whether post-market surveillance detects emerging harms before they become epidemics. The pouch explosion is happening. The regulatory response is still being formulated. The gap between them—measured in years, in millions of users, and in health outcomes that won't be known for decades—is where the future of nicotine is being decided.